دورية أكاديمية
Contemporary American and European Guidelines for Heart Failure Management: JACC: Heart Failure Guideline Comparison.
| العنوان: | Contemporary American and European Guidelines for Heart Failure Management: JACC: Heart Failure Guideline Comparison. |
|---|---|
| المؤلفون: | Ostrominski JW; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., DeFilippis EM; Division of Cardiology, Center for Advanced Cardiac Care, Columbia University Irving Medical Center, New York, New York, USA., Bansal K; Department of Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts, USA., Riello RJ 3rd; Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA., Bozkurt B; Winters Center for Heart Failure, Cardiovascular Research Institute, Baylor College of Medicine and DeBakey VA Medical Center, Houston, Texas, USA., Heidenreich PA; Department of Medicine, VA Palo Alto Healthcare System, Palo Alto, California, USA., Vaduganathan M; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: mvaduganathan@bwh.harvard.edu. |
| المصدر: | JACC. Heart failure [JACC Heart Fail] 2024 May; Vol. 12 (5), pp. 810-825. Date of Electronic Publication: 2024 Mar 13. |
| نوع المنشور: | Journal Article; Review; Comparative Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101598241 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-1787 (Electronic) Linking ISSN: 22131779 NLM ISO Abbreviation: JACC Heart Fail Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Elsevier, [2013]- |
| مواضيع طبية MeSH: | Heart Failure*/therapy , Practice Guidelines as Topic*, Humans ; Europe ; United States ; Cardiology ; American Heart Association ; Disease Management ; Societies, Medical |
| مستخلص: | This review serves to compare contemporary clinical practice recommendations for the management of heart failure (HF), as codified in the 2021 European Society of Cardiology (ESC) guideline, the 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) guideline, and the 2023 focused update of the 2021 ESC document. Overall, these guidelines aim to solidify significant advances throughout the HF continuum since the publication of previous full guideline iterations (2013 and 2016 for the ACC/AHA and ESC, respectively). All guidelines provide new recommendations for an increasingly complex landscape of HF care, with focus on primary HF prevention, HF stages, rapid initiation and optimization of evidence-based pharmacotherapies, overlapping cardiac and noncardiac comorbidities, device-based therapies, and management pathways for special groups of patients, including those with cardiac amyloidosis. Importantly, the ACC/AHA/HFSA document features special emphasis on HF risk prediction and screening, cost/value, social determinants of health, and health care disparities. The review discusses major similarities and differences between these recent guidelines and guideline updates, as well as their potential downstream implications for clinical care. Competing Interests: Funding Support and Author Disclosures Dr DeFilippis serves on a clinical trial committee for Abiomed and has had speaker engagements with AstraZeneca. Dr Riello has served as a consultant for Alexion AstraZeneca, Boehringer Ingelheim, Janssen, Johnson & Johnson, PhaseBio, and Portola. Dr Bozkurt has received personal fees from Vifor for serving on the steering committee for the Care HF Trial; has received personal fees from Amgen, AstraZeneca, and Baxter for serving on advisory committees or for consulting outside the submitted work; has received consulting fees from Bristol Myers Squibb, scPharmaceuticals, Baxter Healthcare Corporation, Sanofi Aventis, Relypsa, and Amgen; has served on the clinical event committee for the GUIDE HF Trial sponsored by Abbott Vascular; and has served on the data safety monitoring committee of the ANTHEM trial sponsored by LivaNova. Dr Vaduganathan has received research grant support from, has served on advisory boards of, or has had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; and has participated on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: comorbidities; guidelines; heart failure; pharmacotherapy; prevention; social determinants of health |
| تواريخ الأحداث: | Date Created: 20240407 Date Completed: 20240508 Latest Revision: 20240604 |
| رمز التحديث: | 20240604 |
| DOI: | 10.1016/j.jchf.2024.02.020 |
| PMID: | 38583167 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2213-1787 |
|---|---|
| DOI: | 10.1016/j.jchf.2024.02.020 |